With new pivotal data, uniQure and CSL Behring dash to the FDA with a potential blockbuster gene therapy for hemophilia B

Nicole DeFeudis

Editor

After a five-month hold put a damper on uniQure’s hemophilia B gene therapy program, things are finally looking up as a positive pivotal readout puts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With new pivotal data, uniQure and CSL Behring dash to the FDA with a potential blockbuster gene therapy for hemophilia B

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With new piv­otal da­ta, uniQure and CSL Behring dash to the FDA with a po­ten­tial block­buster gene ther­a­py for he­mo­phil­ia B

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With new pivotal data, uniQure and CSL Behring dash to the FDA with a potential blockbuster gene therapy for hemophilia B